Step 1 of 2
Review key slides on recent advances in the treatment of metastatic triple-negative breast cancer (mTNBC), with a focus on the evolving role of sacituzumab govitecan and datopotamab deruxtecan as TROP-2–directed antibody–drug conjugates (ADCs) in the first-line setting. Learners will examine the clinical evidence supporting newly approved therapies, compare key phase III trial designs and efficacy and safety data, and explore practical considerations for treatment selection, supportive care planning, and integration of these agents into contemporary treatment algorithms. The activity also highlights emerging ADCs, targeted therapies, and combination strategies that may further expand treatment options for patients with mTNBC.